A missense somatic mutation in JAK2 gene (JAK2 V617F) has recently been reported in chronic myeloproliferative disorders, including polycythemia vera, essential thrombocythemia and myelofibrosis with myeloid metaplasia, strongly suggesting its role in the pathogenesis of myeloid disorders. As activation of JAK2 signaling is occurred in other malignancies as well, we have analysed 558 tissues from common human cancers, including colon, breast and lung carcinomas, and 143 acute adulthood leukemias by polymerase chain reaction -single strand conformation polymorphism analysis. We found three JAK2 mutations in the 113 acute myelogenous leukemias (AMLs) (2.7%), but none in other cancers. The mutations consisted of two V617F mutations and one K607N mutation. None of the AML patients with the JAK2 V617F mutation had a history of previous hematologic disorders. This is the first report on the JAK2 gene mutation in AML, and the data indicated that the JAK2 gene mutation may not only contribute to the development of chronic myeloid disorders, but also to some AMLs.
A missense somatic mutation in JAK2 gene (JAK2 V617F) has recently been reported in chronic myeloproliferative disorders, including polycythemia vera, essential thrombocythemia and myelofibrosis with myeloid metaplasia, strongly suggesting its role in the pathogenesis of myeloid disorders. As activation of JAK2 signaling is occurred in other malignancies as well, we have analysed 558 tissues from common human cancers, including colon, breast and lung carcinomas, and 143 acute adulthood leukemias by polymerase chain reaction -single strand conformation polymorphism analysis. We found three JAK2 mutations in the 113 acute myelogenous leukemias (AMLs) (2.7%), but none in other cancers. The mutations consisted of two V617F mutations and one K607N mutation. None of the AML patients with the JAK2 V617F mutation had a history of previous hematologic disorders. This is the first report on the JAK2 gene mutation in AML, and the data indicated that the JAK2 gene mutation may not only contribute to the development of chronic myeloid disorders, but also to some AMLs. Oncogene (2006 Oncogene ( ) 25, 1434 Oncogene ( -1436 Oncogene ( . doi:10.1038 published online 10 October 2005 Keywords: JAK2; acute myelogenous leukemia; mutation; cancer Myeloproliferative disorders (MPD) include four main types of diseases: chronic myelogeous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET) and myeloid metaplasia with myelofibrosis (MMM) (Dameshek, 1951) . The target of neoplastic transformation in MPD is a multipotent hematopoietic stem cell (Adamson et al., 1976) . However, except for CML, the molecular mechanisms underlying the MPD neoplastic transformation were largely unknown. Recently, several research groups reported a somatic missense mutation in the pseudokinase domain of JAK2 gene (V617F) in most PV (up to 97%) as well as in about one-third of both ET and MMM (Baxter et al., 2005; James et al., 2005; Kralovics et al, 2005; Levine et al., 2005) . Also, the JAK2 V617F mutation was found at a lower frequency in both 'atypical' MPD and myelodysplastic syndromes (MDS) (Steensma et al., 2005) . Functionally, the V617F mutation enhanced the JAK2 kinase activity, and conferred erythropoietin hypersensitivity in the affected cells (Baxter et al., 2005; James et al., 2005; Kralovics et al, 2005; Levine et al., 2005) . In vivo, mice transplanted with bone marrow cells expressing the V617F mutant developed polycythemia (James et al., 2005) . These data suggested that the JAK2 V617F mutation may play a principal role in the pathogenesis of MPD.
Many of the effects of JAK2 activation in the cells are mediated by the signal transducers and activators of transcription (STAT), and JAK2-STAT signaling is frequently activated both in hematologic malignancies and solid tumors (Pallis et al., 2003; Verma et al., 2003) . To see the possibility whether JAK2 mutation is responsible for the JAK2-STAT signaling in common human malignancies, we investigated the JAK2 gene mutation in a large number of human tumors from various origin by polymerase chain reaction (PCR)-based single-strand conformation polymorphism (SSCP) assay in this study.
Methacarn-fixed tissues of 94 breast ductal carcinomas, 104 colorectal carcinomas and 217 non-small cell lung cancers, fresh bone marrow aspirates of 143 acute adulthood leukemias (age range 20-80) were used for this study. The leukemias consisted of nine acute myelogenous leukemias (AMLs) minimally differentiated, 15 AMLs without maturation, 27 AMLs with maturation, nine acute myelomonocytic leukemias, eight acute monoblastic and monocytic leukemias, 12 AML with t(8;21)(q22;q22), two acute erythroid leukemias, 12 acute promyelocytic leukemias (AML with t(15;17) (q22;q12)), six AML with Inv(16)(p13q22), 12 AMLs with multilineage dysplasia, one acute myeloid leukemia and MDS, 14 biphenotypic acute leukemias, two T-cell acute lymphoblastic leukemias (ALL) and 24 B-cell ALLs according to the WHO classification. Approval for this study was obtained from the Catholic University of Korea, College of Medicine's institutional review board.
As all of the JAK2 mutations reported have been 1849G>T in the exon 12, which would result in an amino-acid substitution (V617F) within the JH2 pseudokinase domain (Baxter et al., 2005; James et al., 2005; Kralovics et al, 2005; Levine et al., 2005) , we analysed the exon 12 of JAK2 gene by PCR-SSCP. Genomic DNA each from tumor cells and normal cells were amplified by PCR with one primer pair (5 0 -tggacaacagt caaacaac-3 0 and 5 0 -ctgagaaaggcattagaaag-3 0 ) covering the exon 12. Radioisotope was incorporated into the PCR products for detection by autoradiogram. After SSCP, DNAs showing mobility shifts were cut out from the dried gel, and reamplified for 30 cycles using the same primer sets. Sequencing of the PCR products was carried out using the cyclic sequencing kit (PerkinElmer, Foster City, CA, USA). The procedures of PCR and SSCP analysis were performed as described previously (Shin et al., 2002) . We also confirm the mutation by a direct sequencing. As potential positive controls, we also analysed bone marrow cells of 17 PV patients by the PCR-SSCP followed by DNA sequencing.
PCR-SSCP analysis of the exon 12 of JAK2 gene in the 558 malignancies identified three aberrant bands (Figure 1 ). DNA sequence analysis of the aberrantly migrating bands led to the identification of three JAK2 mutations in 113 AMLs (2.7%), but no JAK2 mutation was detected in the other 445 samples (Figure 1) . None of the normal samples from the same AML patients showed evidence of mutations by the SSCP (Figure 1 ), indicating the mutations had risen somatically. The JAK2 mutations consisted of two 1849G>T (V617F) and one 1821G>C (K607N) (Figure 1 ). According to the subtype of the AML, both of the two V617F mutations were observed in AMLs with t(8;21)(q22;q22), and the K607N mutation was detected in AML without maturation (Table 1 ). The incidence of the V617F was not significantly associated with the cytogenetic abnormality t(8;21)(q22;q22) in the AMLs (Fisher's exact test, P ¼ 0.029). There was no evidence of erythroid lineage proliferation in the bone marrows of the patients with JAK2 mutation. In the PV samples, we could also detect the V617F mutation in 11 out of 17 cases (65%), demonstrating that the PCR-SSCP methods could detect the JAK2 V617F mutation. We analysed the DNAs of peripheral blood momonuclear cells from the 72 healthy persons with the same ethnic background as the patient with the K607N mutation, but found no K607N mutation in them. Also, we checked the public SNP database (NCBI) for this nucleotide substitution 1821G>C (K607N), but found no such substitution, strongly suggesting that the K607N mutation is not a genetic polymorphism. We repeated the experiments twice, including PCR, SSCP and sequencing analysis to ensure the specificity of the results, and found that the data were consistent (data not shown).
The SSCP of all AML cases with the JAK2 mutations at the mutation sites showed both wild-type and aberrant bands (Figure 1) , and direct sequencing analysis also revealed both mutant and wild-type sequences (data not shown), indicating the JAK2 mutations were heterozygous. By contrast, according to the SSCP (Figure 1 ) and direct DNA sequencing analysis (data not shown), six out of 11 JAK2 V617F mutations in PV were homozygous.
Broadly, myeloid neoplasia could be categorized into AML, MDS and MPD. The common feature of myeloid neoplasm is an origin in a progenitor cells producing terminally differentiated cells of myeloid series (Adamson et al., 1976) . As JAK2 V617F mutation has been found in MPD (Baxter et al., 2005; James et al., 2005;  Kralovics et al, 2005; Levine et al., 2005) , MDS (Steensma et al., 2005) and AML, it is conceivably possible that AML, another myeloid stem cell disorder, might also harbor the JAK2 mutation. Although STAT signaling activation has been reported in most AML cases, the cause of constitutive STAT activation in AML is still elusive (Pallis et al., 2003) . We hypothesized that JAK2 mutation could partly be responsible to the STAT activation in AML.
In this study, we discovered that 2.7% of the AMLs harbored JAK2 mutation. Compared to the incidence of JAK2 mutation in PV, ET and MMM (Baxter et al., 2005; James et al., 2005; Kralovics et al, 2005; Levine et al., 2005) , the incidence of JAK2 mutation in AML is very low. However, the incidence of JAK2 mutation in AML is similar to those in atypical MPD and MDS. These data suggest that JAK2 mutation might be widespread among the myeloid disorders, but the incidence may vary depending on the type of the myeloid disorders. Also, absence of the JAK2 mutation in other common malignancies suggests that occurrence of JAK2 mutation might be limited in the myeloid disorders.
Although STAT signaling activation has been reported in most AML cases, the cause of constitutive STAT activation in AML is still elusive (Pallis et al., 2003) . Detection of JAK2 V617F mutations, which had been proved to be an activating mutation, in AML indicated that the JAK2 mutation is partly responsible for the JAK2-STAT signaling activation in AML. In the present study, we also found a novel JAK2 mutation (K607N) in the pseudokinase domain. The amino-acid K607 in JAK2 is conserved in both human and mouse species (Genbank database), and is conserved in JAK1 of both human and mouse species (Genbank database), suggesting that alteration of this conserved amino acid could possible alter the function of JAK2. However, the consequence of this mutation in leukemia pathogenesis remains elusive at this stage.
As both MPD and MDS tend to evolve over time to AML (Swolin et al., 1988) , it is possible that the JAK2 mutations detected in this study might have originated from the previous hematologic disorders. However, in the clinical information of the patients we could not identify any specific finding that suggested earlier hematologic disorders of the patients. Furthermore, the t(8;21)(q22;q22) identified in the two AMLs with the V671F mutation is rare in PV or the secondary AML evolved from PV, either (Swolin et al., 1988; DiezMartin et al., 1991) . Finally, a previous report on JAK2 mutation in PV described that an acute leukemia cell line (human erythroleukemia cell line) harbored the JAK2 V617F mutation . These observations also suggested that the JAK2 mutations in this study originated from de novo AML.
In summary, this study identified that AML harbored JAK2 mutation, suggesting some overlap of pathogenesis in both MPD and AML. The most impressive examples of recent cancer therapies used the kinase inhibitors such as Imanitib (Gleevec), Trastzumab (Herceptin) and Gefitinib (Iressa) (Druker et al., 2001; Arteaga et al., 2002; Wakeling et al., 2002) . Thus, research will further focus on evaluating kinases as promising molecular targets for cancer treatment. As all of the JAK2 mutations except K607N mutation have been an identical activating mutation (V617F), JAK2 mutation could be a potential antineoplastic target. Based on the high incidence of JAK2 mutation, PV, ET and MMM should first be the candidate diseases for such anti-JAK2 therapies. Despite the infrequent incidence of JAK2 mutation in de novo AML, mutated JAK2 could also be therapeutically targeted in some AMLs with JAK2 mutation. Inhibition of human erythroleukemia cell proliferation in vitro with the V617F mutation by a small molecule inhibitor of JAK2 supports this idea .
